Ajith Malige

Ajith Malige

Auto-generated profile, based on publicly available information

Ajith Malige

Cedars-Sinai Kerlan-Jobe Institute, Los Angeles, California, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Clinical Biomechanics
Verified
Journal Article
Closed access
AMAjith Malige
Ajith Malige
SBSoroush Baghdadi
Soroush Baghdadi
MHMichael W. Hast
Michael W. Hast
ESElaine C. Schmidt
Elaine C. Schmidt
KSKevin G. Shea
Kevin G. Shea
TGTheodore J. Ganley
Theodore J. Ganley

26 March 2022 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
AMAjith Malige
Ajith Malige
APAnna N. Pellegrino
Anna N. Pellegrino
KKKelcei Kunkle
Kelcei Kunkle
AKAndrew K. Konopitski
Andrew K. Konopitski
PBPatrick J. Brogle
Patrick J. Brogle
CNChinenye O. Nwachuku
Chinenye O. Nwachuku

22 June 2024 in Journal of Orthopaedics
Verified
Journal Article
Closed access
AMAjith Malige
Ajith Malige
CGCarson Gates
Carson Gates
JCJames L. Cook
James L. Cook

1 November 2020 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Closed access
AMAjith Malige
Ajith Malige
SYShawn Yeazell
Shawn Yeazell
ANAnna Ng-Pellegrino
Anna Ng-Pellegrino
GCGregory Carolan
Gregory Carolan

1 June 2018 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
VLVince W. Lands
Vince W. Lands
AMAjith Malige
Ajith Malige
ACAldo Carmona
Aldo Carmona
CRChristopher R. Roscher
Christopher R. Roscher
RGRobert S. Gayner
Robert S. Gayner
WDWilliam G. DeLong
William G. DeLong

1 June 2019 in Spine
Verified
Journal Article
Closed access
AMAjith Malige
Ajith Malige
GSGbolabo Sokunbi
Gbolabo Sokunbi
Study Design.: A retrospective chart review. Objective.: The aim of this study was to address and characterize the differences between pain relief obtained from the “trial” versus permanent stimulator in the acute postoperative period (less than 6 weeks). Summary of Background Data.: After a short stimulator trial (typically less than 7 days), patients who report at least a 50% relief are set up for permanent spinal cord stimulator (SCS) placement. The literature has shown that a subset of patients develop tolerance to these stimulating therapies, often resulting in reduced efficacy of symptom relief as early as 2 years post-permanent implantation. Methods.: Between the years of 2013 and 2017, 241 patient charts who underwent a successful trial and had a subsequent permanent SCS placed by a fellowship-trained surgeon through an open incision were reviewed. For each patient, demographic information, numerical rating system (NRS) pain scores, Oswestry Disability Index (ODI) scores, and opioid medication usage were recorded and stratified by time-period (before trial, after trial and before permanent placement, and after permanent SCS placement). Results.: Of the 100 included patients, 60 were female; 60 patients had previous failed lumbar surgery (53%). Placement of trial stimulator (median = 4) decreased pain scores significantly more than permanent spinal cord stimulator did (median = 2) (P = 0.00). No significant difference was seen in ODI score difference between trial and initial scores (median = 4) and final and initial scores (median = 6) (P = 0.64). Finally, a significantly higher decrease in pain medication usage was seen after trial initiation (median = 0) versus after permanent spinal cord stimulator placement (median = 0) (P = 0.028). Twenty-two patients (22%) had reported complications, with 15 complaining of prolonged surgical site pain. Conclusion.: Discrepancies observed in symptom alleviation between percutaneous trials and permanent placement in the acute 6-week postop period can have a significant effect on patient perceived outcomes. Understanding these issues will help in providing preoperative counseling and managing postoperative expectations. Level of Evidence: 4